{"preliminary_commentary":{"by_channel":{"x_thread":18,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06238843\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"G-HOPE-001","nct_id":"NCT06238843","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=g-hope-001-nct06238843. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"G-HOPE-001","arms":[{"description":"There are three drugs ( irinotecan, paclitaxel,or FTD/TPI (only are applicable in US/EU/Japan and other regions where FTD/TPI is approved for GC treatment)) in active contral arm, the subjects will receive the drug based on investigator's choice","label":"Active Comparator: control arm","type":"ACTIVE_COMPARATOR"},{"description":"IBI343: Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles .","label":"IBI343 monotherapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma"],"enrollment":{"count":464,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）","otherNames":[],"type":"DRUG"},{"name":"IBI343","otherNames":["Arcotatug Tavatecan"],"type":"DRUG"}],"last_update":"2026-05-13","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","official_title":"A Multicenter, Randomized, Open-label, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-12-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"progression free survival(PFS)","timeFrame":"within approximately 20 months"},{"measure":"overall survival(OS)","timeFrame":"within approximately 26 months"}],"references":[],"start_date":{"date":"2024-06-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)","url":"https://clinicaltrials.gov/study/NCT06238843"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/g-hope-001-nct06238843"}